AR087062A1 - Composicion y metodo para prevenir un sindrome o para reducir el riesgo de que se desarrolle - Google Patents

Composicion y metodo para prevenir un sindrome o para reducir el riesgo de que se desarrolle

Info

Publication number
AR087062A1
AR087062A1 ARP120102430A ARP120102430A AR087062A1 AR 087062 A1 AR087062 A1 AR 087062A1 AR P120102430 A ARP120102430 A AR P120102430A AR P120102430 A ARP120102430 A AR P120102430A AR 087062 A1 AR087062 A1 AR 087062A1
Authority
AR
Argentina
Prior art keywords
gal
risk
development
reduce
prevent
Prior art date
Application number
ARP120102430A
Other languages
English (en)
Inventor
Tzortzis Georgios
Vulevic Jelena
Original Assignee
Clasado Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Clasado Inc filed Critical Clasado Inc
Publication of AR087062A1 publication Critical patent/AR087062A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Uso de una composición de galactooligosacáridos para prevenir un síndrome, particularmente el síndrome metabólico, o para reducir el riesgo de que se desarrolle. Reivindicación 1: Una composición caracterizada porque comprende una mezcla de galactooligosacáridos, que en particular comprende los disacáridos Gal (b1-3)-Glc, Gal (b1-3)-Gal, Gal (b1-6)-Gal y Gal (a1-6)-Gal, los trisacáridos Gal (b1-6)-Gal (b1-4)-Glc y Gal (b1-3)-Gal (b1-4)-Glc, el tetrasacárido Gal (b1-6)-Gal (b1-6)-Gal (b1-4)-Glc y el pentasacárido Gal (b1-6)-Gal (b1-6)-Gal (b1-6)-Gal (b1-4)-Glc, que puede usarse en un método para prevenir el síndrome metabólico o para reducir el riesgo de que se desarrolle.
ARP120102430A 2011-07-05 2012-07-04 Composicion y metodo para prevenir un sindrome o para reducir el riesgo de que se desarrolle AR087062A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB1111452.7A GB2492559B (en) 2011-07-05 2011-07-05 Composition and method for preventing or reducing the risk of developing a syndrome

Publications (1)

Publication Number Publication Date
AR087062A1 true AR087062A1 (es) 2014-02-12

Family

ID=44512110

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP120102430A AR087062A1 (es) 2011-07-05 2012-07-04 Composicion y metodo para prevenir un sindrome o para reducir el riesgo de que se desarrolle

Country Status (24)

Country Link
US (2) US11052097B2 (es)
EP (1) EP2729152B1 (es)
JP (1) JP2014518253A (es)
KR (1) KR20140041597A (es)
CN (2) CN103648504A (es)
AR (1) AR087062A1 (es)
AU (1) AU2012203730B2 (es)
BR (1) BR112013030308A2 (es)
CA (1) CA2838309C (es)
CY (1) CY1117170T1 (es)
DK (1) DK2729152T3 (es)
ES (1) ES2562993T3 (es)
GB (1) GB2492559B (es)
HU (1) HUE027148T2 (es)
IL (1) IL230251A (es)
MX (1) MX337612B (es)
MY (1) MY173722A (es)
PL (1) PL2729152T3 (es)
PT (1) PT2729152E (es)
RU (1) RU2571079C2 (es)
TW (1) TWI461200B (es)
UA (1) UA111616C2 (es)
WO (1) WO2013005001A1 (es)
ZA (1) ZA201308776B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2492559B (en) * 2011-07-05 2018-07-25 Clasado Inc Composition and method for preventing or reducing the risk of developing a syndrome
GB201319538D0 (en) 2013-11-05 2013-12-18 Optibiotix Health Ltd Composition
KR102029263B1 (ko) * 2018-05-16 2019-11-08 주식회사 비피도 베타-엘-푸코피라노실-(1→3)-옥시-디-갈락토피라노오스를 포함하는 프리바이오틱스 조성물
GB2623336A (en) * 2022-10-12 2024-04-17 Clasado Res Services Limited Compositions and uses thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62210965A (ja) * 1986-03-13 1987-09-17 Shokuhin Sangyo Baioriakutaa Syst Gijutsu Kenkyu Kumiai 低カロリ−飲食品およびその製造方法
JP2699470B2 (ja) * 1988-10-19 1998-01-19 大日本インキ化学工業株式会社 食品保存剤及びその製造方法
US6368591B2 (en) * 1998-05-15 2002-04-09 Shanghai Sine Pharmaceutical Corporation Ltd. Beneficial microbe composition, new protective materials for the microbes, method to prepare the same and uses thereof
RU2280447C2 (ru) * 1999-09-17 2006-07-27 Новартис Аг Способ лечения нарушений метаболизма, прежде всего диабета или заболеваний или состояний, связанных с диабетом
JP2003339348A (ja) * 2002-05-27 2003-12-02 Toyo Shinyaku:Kk 健康食品
GB0315266D0 (en) * 2003-06-30 2003-08-06 Clasado Inc Novel galactooligosaccharide composition and the preparation thereof
PL1644482T5 (pl) 2003-06-30 2015-05-29 Clasado Inc Nowa kompozycja galaktooligosacharydów i jej wytwarzanie
DE102005034262A1 (de) * 2005-07-22 2007-01-25 Bayer Healthcare Ag Substituierte Pyridocarboxamide II
WO2008054193A1 (en) * 2006-11-02 2008-05-08 N.V. Nutricia Nutritional products that comprise saccharide oligomers
EP2143341A1 (en) 2008-07-08 2010-01-13 Nestec S.A. Nutritional Composition Containing Oligosaccharide Mixture
GB0809921D0 (en) * 2008-05-30 2008-07-09 Clasado Inc Product and process therefor
JP5238373B2 (ja) * 2008-06-25 2013-07-17 株式会社ヤクルト本社 腸間膜脂肪低減剤
GB0906983D0 (en) * 2009-04-23 2009-06-03 Clasado Inc Novel use
CA2763384C (en) * 2009-05-27 2014-07-08 Clasado Inc Use of a composition of a mixture of galactooligosaccharides for preventing diarrhoea
US8951512B2 (en) * 2010-05-04 2015-02-10 New York University Methods for treating bone disorders by characterizing and restoring mammalian bacterial microbiota
GB2492559B (en) * 2011-07-05 2018-07-25 Clasado Inc Composition and method for preventing or reducing the risk of developing a syndrome
GB201305708D0 (en) * 2013-03-28 2013-05-15 Clasado Inc Novel use

Also Published As

Publication number Publication date
GB2492559A (en) 2013-01-09
MX337612B (es) 2016-03-10
MX2013015036A (es) 2014-02-17
MY173722A (en) 2020-02-18
CA2838309A1 (en) 2013-01-10
PT2729152E (pt) 2016-03-04
WO2013005001A1 (en) 2013-01-10
CY1117170T1 (el) 2017-04-05
KR20140041597A (ko) 2014-04-04
CN107744522A (zh) 2018-03-02
CN103648504A (zh) 2014-03-19
GB2492559B (en) 2018-07-25
NZ617764A (en) 2015-08-28
GB201111452D0 (en) 2011-08-17
BR112013030308A2 (pt) 2016-11-29
IL230251A (en) 2017-03-30
PL2729152T3 (pl) 2016-06-30
HUE027148T2 (en) 2016-10-28
AU2012203730A1 (en) 2013-01-24
RU2571079C2 (ru) 2015-12-20
EP2729152B1 (en) 2015-12-30
JP2014518253A (ja) 2014-07-28
ZA201308776B (en) 2015-04-29
DK2729152T3 (en) 2016-01-25
ES2562993T3 (es) 2016-03-09
US20140142061A1 (en) 2014-05-22
RU2014103800A (ru) 2015-08-10
CA2838309C (en) 2017-04-18
US11052097B2 (en) 2021-07-06
AU2012203730B2 (en) 2013-10-31
TWI461200B (zh) 2014-11-21
UA111616C2 (uk) 2016-05-25
TW201313235A (zh) 2013-04-01
EP2729152A1 (en) 2014-05-14
US20210330688A1 (en) 2021-10-28

Similar Documents

Publication Publication Date Title
ECSP10010106A (es) Trans-clomifeno para el síndrome metabólico
CL2016000882A1 (es) Composiciones de arni contra el componente c5 del complemento y métodos para su uso (divisional de sol. n°2710-15).
CL2011000851A1 (es) Composicion farmaceutica que comprende al menos una insulina y al menos un agonista de glp-1; metodo de preparacion; su uso para tratar diabetes o prevenir la disfuncion de celulas beta pancreaticas; kit; y dispositivo.
CL2013001433A1 (es) Composicion que comprende al menos una n-acetil lactosamina, al menos un oligosacarido sialilado al menos un oligosacarido fucosilado; y su uso en la prevencion de infecciones respiratorias agudas y/o para aliviar los sintomas de dichas infecciones.
SV2010003673A (es) Compuestos heterociclicos novedosos y usos de los mismos
WO2010148364A3 (en) Solver-based visualization framework
AR087845A1 (es) Articulos estables solubles en agua de dosis unitaria
BR112013017845A2 (pt) agente antidiabético de abaixamento de lipídio
DOP2014000133A (es) Triazolopiridinas sustituidas
UY31789A1 (es) Composiciones de insulina de super rápida actuación
ECSP13013011A (es) Triazolopiridinas
EA201592134A1 (ru) Синергетические композиции
AR087062A1 (es) Composicion y metodo para prevenir un sindrome o para reducir el riesgo de que se desarrolle
SV2017005466A (es) Pirazolpiridinaminas como inhibidores de mknk1 y mknk2
DOP2013000254A (es) Composiciones de limpieza de sal colina
BR112014006597A2 (pt) composições de interomônio e seu uso para modificar comportamento em espécies de vertebrado diferentes
AR095738A1 (es) Tratamiento para disfunción cognitiva
BR112013013117A2 (pt) agente hidrotrópico, uso do mesmo para tornar solúveis tensoativos não iônicos e composições contendo os mesmos
BR112016007487A2 (pt) composições compreendendo citrulina e leucina e seu uso no tratamento de diabetes e de síndrome meta-bólica
BR112014007150A2 (pt) artigos abrasivos de redução de ruído
BR112018001486A2 (pt) ?composição de limpeza em barra, processo para preparar a composição, método para reduzir atividade antimicrobiana em uma superfície e uso da composição?
CL2012001835A1 (es) Uso de una formulacion que comprende un agente viscogenico y moxifloxacina para preparar un medicamento util para tratar el oido medio.
BR112014029138A2 (pt) uso de composições oligo-quaternárias para aumentar tempo de vida do inibidor de incrustação em uma formação subterrânea
AR074302A1 (es) Trans-clomifeno para el sindrome metabolico y la diabetes mellitus tipo 2.. metodo
BR112014002372A2 (pt) recuperação de petróleo

Legal Events

Date Code Title Description
FB Suspension of granting procedure